Kanabo Group PLC Notice of Annual General Meeting (1660C)
08 Junho 2023 - 1:20PM
UK Regulatory
TIDMKNB
RNS Number : 1660C
Kanabo Group PLC
08 June 2023
8 June 2023
Kanabo Group plc
("Kanabo", the "Group" or the "Company")
Notice of Annual General Meeting
Kanabo Group plc (LSE: KNB), the patient focused healthcare
technology and medicinal cannabis company, announces the Notice of
Annual General Meeting ("Notice of Meeting") has now been
published. The document has been posted to shareholders and is now
available to download from the Company's website:
https://www.kanabogroup.com/
The Company's Annual General Meeting is scheduled to be help on
Friday, 30 June 2023 at Asserson Law Offices of Central Court, 25
Southampton Buildings, Holborn, London WC2A 1AL. The meeting will
commence at 1.00 p.m.
The voting results of all resolutions put before the 2023 AGM
will be announced shortly afterwards.
Enquiries:
Kanabo Group plc via Vigo Consulting
Avihu Tamir, Chief Executive Officer +44 (0)20 7390 0230
Assaf Vardimon, Chief Financial Officer
Ian Mattioli, Non-Executive Chair of the Board
Peterhouse Capital Ltd (Financial Adviser
and Broker)
Eran Zucker / Lucy Williams / Charles Goodfellow +44 (0)20 7469 0930
Vigo Consulting (Financial Public Relations/Investor
Relations)
Jeremy Garcia / Fiona Hetherington / Verity
Snow +44 (0)20 7390
kanabo@vigoconsulting.com 0230
About Kanabo Group Plc
Kanabo Group Plc (LSE:KNB) is a healthtech company committed to
revolutionising patient care through its innovative technology
platform and disruptive product offerings. Since its inception in
2017, Kanabo has been focused on researching, developing, and
commercialising regulated medicinal cannabis-derived formulations
and therapeutic inhalation devices.
Kanabo's NHS-approved online telehealth platform, The GP
Service, provides patients with video consultations, online
prescriptions, and primary care services. The Company is a leader
in its field, focusing on improving patient outcomes and providing
more accessible healthcare experiences.
In March 2023, Kanabo successfully launched its Pain Clinic,
Treat It, under the expert guidance of its technological and
product expertise. Treat It initially focuses on chronic pain
management using plant-based medicine and treatments that are
currently unavailable through traditional channels.
At Kanabo Group Plc, we are dedicated to providing patients with
the highest quality medical treatments and more accessible
healthcare experiences.
Visit www.kanabogroup.com for more information.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOAUPUAGQUPWGQR
(END) Dow Jones Newswires
June 08, 2023 12:20 ET (16:20 GMT)
Kanabo (LSE:KNB)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Kanabo (LSE:KNB)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
